Home News & Events Press releases Press releases Page tools Share Share Share on FacebookShare on XShare on LinkedinShare on Bluesky Print Search Email Accessibility Category AcquisitionsAwardsCorporate earningsESGInvestor conferencesLeadershipTechnologyWhitepaper Year 2026202520242023202220212020201920182017 In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events Webinars Workshops Webinars Social media Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media What’s happening in ICON ICON Plc On 30 March – 2 April at the World Vaccine Congress, speak with ICON experts at booth 222 to learn how our experience across 180+ vaccine studies, end‑to‑end product development expertise, and fully integrated vaccine‑de... 20h View post View webpage ICON Plc How is AI transforming vaccine‑trial execution? On 31 March at 11:40 am at the World Vaccine Congress, join our interactive working group session, “Vaccine trials: How AI shifts execution from static plans to living sys... 22h View post View webpage ICON Plc Rare autoimmune diseases can leave patients particularly vulnerable to infection, but they often require unique considerations for vaccination. Learn what makes these cases so unique, and what to take into account when b... 23h View post View webpage ICON Plc Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil... 11 Mar View post View webpage ICON Plc Join ICON’s Dr. Anne Behringer on 25 March at 03:00 for a virtual presentation on “Cross-Border Recruitment in Clinical Trials: A Perspective on Operational Reality”. Learn more https://ow.ly/o25L50Yr8W3 11 Mar View post View webpage ICON Plc Attending #OCTSoutheast 10-11 March? Stop by booth \#37 to learn how we support biotechs with flexible clinical development, operational expertise and data‑driven decision‑making. https://lnkd.in/ehPmQF\_H 10 Mar View post View webpage ICON Plc From feasibility to activation, study start-up delays can erode momentum and inflate costs. ICON’s Brian Mallon offers perspective and outlines practical fixes, including AI-driven contracting, early site engagement, and... 10 Mar 2 View post View webpage ICON Plc Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a... 10 Mar View post View webpage ICON Plc ICON has participated in 193 neurodegenerative and neuromuscular studies, enrolling 18,200+ patients at 4,800+ sites globally. Meet our experts at #ADPD2026, booth \#29 to learn how we can support your neurodegeneration ... 10 Mar View post View webpage ICON Plc The type of immunosuppressive treatment a patient with a rare autoimmune condition receives may impact how they respond to vaccines. Read our new article to explore this and other factors that can help determine the best... 9 Mar View post View webpage ICON Plc Only one day until #OCT Southeast begins. ICON will be on site 10–11 March, ready to connect with biotechs looking to strengthen clinical delivery. Visit Booth \#37 to meet our team and discuss how our expertise supports... 9 Mar View post View webpage ICON Plc Meet the ICON team at Medidata NEXT New York. Our specialists will be available throughout the event to discuss how ICON is supporting sponsors to improve study build quality, streamline delivery and adopt technology wit... 9 Mar View post View webpage
